Journal
LUNG CANCER
Volume 86, Issue 1, Pages 113-114Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2014.07.021
Keywords
Erlotinib; Interstitial lung disease; Pharmacokinetics; High exposure; ABCG2; Polymorphism